Prakash Chandra, Shaffer Christopher L, Nedderman Angus
Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340, USA.
Mass Spectrom Rev. 2007 May-Jun;26(3):340-69. doi: 10.1002/mas.20128.
With the dramatic increase in the number of new chemical entities (NCEs) arising from combinatorial chemistry and modern high-throughput bioassays, novel bioanalytical techniques are required for the rapid determination of the metabolic stability and metabolites of these NCEs. Knowledge of the metabolic site(s) of the NCEs in early drug discovery is essential for selecting compounds with favorable pharmacokinetic credentials and aiding medicinal chemists in modifying metabolic "soft spots". In development, elucidation of biotransformation pathways of a drug candidate by identifying its circulatory and excretory metabolites is vitally important to understand its physiological effects. Mass spectrometry (MS) and nuclear magnetic resonance (NMR) have played an invaluable role in the structural characterization and quantification of drug metabolites. Indeed, liquid chromatography (LC) coupled with atmospheric pressure ionization (API) MS has now become the most powerful tool for the rapid detection, structure elucidation, and quantification of drug-derived material within various biological fluids. Often, however, MS alone is insufficient to identify the exact position of oxidation, to differentiate isomers, or to provide the precise structure of unusual and/or unstable metabolites. In addition, an excess of endogenous material in biological samples often suppress the ionization of drug-related material complicating metabolite identification by MS. In these cases, multiple analytical and wet chemistry techniques, such as LC-NMR, enzymatic hydrolysis, chemical derivatization, and hydrogen/deuterium-exchange (H/D-exchange) combined with MS are used to characterize the novel and isomeric metabolites of drug candidates. This review describes sample preparation and introduction strategies to minimize ion suppression by biological matrices for metabolite identification studies, the application of various LC-tandem MS (LC-MS/MS) techniques for the rapid quantification and identification of drug metabolites, and future trends in this field.
随着组合化学和现代高通量生物测定产生的新化学实体(NCEs)数量急剧增加,需要新的生物分析技术来快速测定这些NCEs的代谢稳定性和代谢产物。在药物早期研发阶段,了解NCEs的代谢位点对于选择具有良好药代动力学特性的化合物以及帮助药物化学家修饰代谢“弱点”至关重要。在药物开发过程中,通过鉴定药物候选物的循环和排泄代谢产物来阐明其生物转化途径对于理解其生理效应至关重要。质谱(MS)和核磁共振(NMR)在药物代谢产物的结构表征和定量方面发挥了不可估量的作用。事实上,液相色谱(LC)与大气压电离(API)MS联用现已成为快速检测、结构解析和定量各种生物流体中药物衍生物质的最强大工具。然而,通常仅靠MS不足以确定氧化的确切位置、区分异构体或提供异常和/或不稳定代谢产物的精确结构。此外,生物样品中过量的内源性物质常常会抑制与药物相关物质的电离,使通过MS鉴定代谢产物变得复杂。在这些情况下,多种分析和湿化学技术,如LC-NMR、酶水解、化学衍生化以及与MS联用的氢/氘交换(H/D交换),被用于表征药物候选物的新型和异构代谢产物。本综述描述了用于代谢产物鉴定研究的样品制备和引入策略,以尽量减少生物基质对离子的抑制,各种LC串联MS(LC-MS/MS)技术在药物代谢产物快速定量和鉴定中的应用,以及该领域的未来趋势。